Necrolytic migratory erythema: A cutaneous clue to glucagonoma syndrome

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 5, 2004, Pages 591-595

  Remes Troche, J M ^a   Garcia de Acevedo B ^a   Zuniga Varga J ^a   Avila Funes, A ^a   Orozco Topete, R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Glucagonoma syndrome; Necrolytic migratory erythema

Indexed keywords

ANTIBIOTIC AGENT; DACARBAZINE; DAPSONE; FLUOROURACIL; GLUCAGON; METHOTREXATE; NICOTINAMIDE; STEROID; STREPTOZOCIN; TAR; TUBERCIDIN; VITAMIN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ERYTHEMA; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NECROLYTIC MIGRATORY ERYTHEMA; PANCREAS RESECTION; PARAKERATOSIS; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; SKIN MANIFESTATION; SPLENECTOMY; ULTRAVIOLET RADIATION;

DIAGNOSIS, DIFFERENTIAL; EXANTHEMA; GLUCAGON; GLUCAGONOMA; HUMANS; LEG; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; SPLENECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4544367640     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00981.x     Document Type: Article

References (30)

1. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilol 1942; 45: 1069-1080.
2. McGravan MH, Unger RH, Recant L et al. A glucagon secreting alpha cell carcinoma of the pancreas. N Engl J Med 1966; 274: 1408-1413.
3. Soga J, Yasuko Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS). A statistical evaluation of 407 reported cases. J Hepato Biliary Pancreat Surg 1998; 5: 312-319.
4. Edney JA, Hofmann S, Thompson JS et al. Glucagonoma syndrome is an underdiagnosed entity. Am J Surg 1990; 160: 625-629.
5. Wermers RA, Fatourechi V, Wynne AG et al. The glucagonoma syndrome. Medicine 1996; 75: 53-63.
6. Shupak JL, Berczeller PH, Stevens DM. The glucagonoma syndrome. J Dermatol Surg Oncol 1978; 4: 242-247.
7. Keiher SM, Omura EF, Grizzle WE et al. Histologic variation in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol 1986; 10: 445-453.
8. Schwartz RA. Glucagonoma and pseudoglucagonoma syndromes. Int J Dermatol 1997; 36: 81- 89.
9. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol 1998; 38: 866-873.
10. Mozell E, Stenzel P, Weltering EA et al. Functional endocrine tumors of the pancreas. Clinical presentation, diagnosis, and treatment. Curr Probl Surg 1990; 27: 301-386.
11. Stacpoole PW. The glucagonoma syndrome. Clinical features, diagnosis, and treatment. Endocr Rev 1981; 2: 347-361.
12. Boden G. Insulinoma and glucagonoma. Semin Oncol 1987; 14: 253-262.
13. Holmes A, Kilpatrick C, Proietto J et al. Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma. Am J Med 1991; 91: 434-436.
14. Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagon-producing islet cell tumors. Am J Gastroenterol 1981; 76: 125-131.
15. Mallison CN, Bloom SR, Warin AP et al. A glucagonoma syndrome. Lancet 1974; 2: 1-5.
16. Smith AP, Doolas A, Staten ED. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol 1996; 61: 306-309.
17. Klein S, Jahoor F, Baba E et al. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metab Clin Exp 1992; 41: 1171-1175.
18. Abraira C, DeBartolo M, Katzen R, Lawrence AM. Disappearance of glucagonoma rash after surgical resection, but not during dietary normalization of serum amino acids. Am J Clin Nutrit 1984; 39: 351-355.
19. Fujita S, Seino Y, Ishida H et al. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome. Cancer 1986; 57: 860-865.
20. Schmid R, Allescher HD, Schepp W et al. Effect of somarostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma syndrome. Hepato-gastroenterol 1988; 35: 34-37.
21. Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illness. Diabetes 1971; 20: 834-838.
22. Rosch T, Lightdale CJ, Botet JF et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721-1726.
23. Weinel RJ, Neuhaus C, Stapp C et al. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg 1993; 218: 640.
24. Wynick D, Hammond PJ, Bloom SR. The glucagonoma syndrome. Clin Dermatol 1993; 11: 93-97.
25. McEntee GP, Nagorney DM, Kvols LK et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091-1096.
26. Alsina AE, Barthus S, Hull D et al. Liver transplant for metastatic neuroendocrine tumor. J Clin Gastroenterol 1990; 12: 533-537.
27. Arnold J, O'Grady J, Bird G et al. Liver transplantation for primary and secondary hepatic apudomas. Br J Surg 1989; 76: 248-249.
28. Frankton S, Bloom SR. Gastrointestinal endocrine tumors. Glucagonomas. Bailliere's Clin Gastroenterol 1996; 10: 697-705.
29. Reyes-Govea J, Holm A, Aldrete JS. Response of glucagonomas to surgical excision and chemotherapy. Am Surg 1989; 55: 523-527.
30. Van der Loos TLJM, Lambrecht ER, Lambers JCCA. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol 1987; 16: 468-472.